Erythromycin

Oral Antibiotics

Drug class: Macrolide Antibiotics

Erythromycin (ERYTHROCIN)（中文：紅霉素）

Common Strengths

• Tablet/Capsule 250 mg, 500 mg
• Oral suspension 125 mg/5 mL

Drug Trade Names

Erythrocin

Drug Usage

The macrolides have an antibacterial spectrum similar but not identical to penicillin; they are thus an alternative in penicillin-allergic patients.

Erythromycin is indicated for:

• Respiratory tract infections (including pneumonia, whooping cough, Legionella, chlamydia, and mycoplasma infection)
• Skin infections
• Diphtheria
• Intestinal amebiasis
• Acute pelvic inflammatory disease
• Syphilis
• Prevention of rheumatic fever in penicillin-allergic patients
• Acne, rosacea

Mechanism of Action

Erythromycin works as a bacteriostatic agent by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, blocking peptide chain elongation, which prevent bacterial growth without directly killing the bacteria.

Route of Administration

Erythromycin can be administered via:

• Oral (tablets, capsules, oral suspension)
• Topical (for skin conditions)

Dosages

Normal Adults:

• Typical oral dosage: 250 mg to 500 mg every 6 hours; maximum 4 grams per day.

Renal Impairment, maximum 1.5 g daily in sever renal impairment.

Dosage adjustments may be necessary based on eGFR:

• eGFR ≥60 mL/min: No adjustment needed.
• eGFR 30-59 mL/min: Use with caution.
• eGFR <30 mL/min: Consult healthcare provider for specific dosing adjustments.

Side Effects

Frequency	Adverse reactions
Common Side Effects	Gastrointestinal disturbances (nausea, vomiting, diarrhea)
	Abdominal pain
	Rash
Serious Side Effects	Liver toxicity (elevated liver enzymes)
	QT prolongation (risk of arrhythmias)
	Hearing loss (especially in older adults)

Pharmacokinetics

• Hepatic Metabolism: Erythromycin undergoes extensive metabolism primarily in the liver via the cytochrome P450 enzyme CYP3A4. Approximately 80% of the drug is metabolized through demethylation.
• First-pass metabolism significantly reduces the amount of active drug entering systemic circulation after oral dosing.
• Excretion: Erythromycin is primarily eliminated via bile (60%–80%), with minimal renal excretion (2%–15% unchanged). This highlights its hepatic clearance as a key component of its pharmacokinetic profile.
• Elimination half-life varies based on dosing frequency and individual patient factors. It ranges from approximately 1.5 to 3.5 hours in healthy individuals.
• The onset of action for erythromycin taken orally is approximately 1 hour after administration.
• The duration of action for orally administered erythromycin typically ranges from 6 to 12 hours.

Drug Precautions

Pregnancy

Generally considered safe; minimal risk to the fetus.

Breastfeeding

Passes into breast milk but considered for nursing infants.

Children and Elderly

Safe for children; elderly patients may have increased sensitivity to side effects such as hearing loss and arrhythmias.

Drug Monitoring Items

Liver function test should be monitored regularly due to potential hepatotoxicity.

Patient Education

• Symptoms of liver dysfunction (e.g jaundice, dark urine, severe fatigue).
• Signs of electrolyte imbalance (e.g. muscle weakness, irregular heartbeat).
• Symptoms indicative of severe gastrointestinal issues, such as persistent diarrhea or abdominal pain, may suggest Clostridium difficile infection.

Drug Interactions

Erythromycin can interact with various medications, particularly those metabolized by cytochrome P450 enzymes, leading to increased toxicity or reduced efficacy of other drugs.

Major Interactions, examples include:

• Anticoagulants: Erythromycin can enhance the effects of anticoagulants like warfarin and rivaroxaban, increasing the risk of bleeding.
• Statins: It can elevate serum levels of statins such as simvastatin and atorvastatin, leading to an increased risk of statin-related myopathy or rhabdomyolysis.
• QT-prolonging Agents: Concurrent use with drugs like terfenadine, astemizole, and pimozide can increase the risk of life-threatening arrhythmias due to QT interval prolongation.
• Benzodiazepines: Erythromycin can increase the sedative effects of benzodiazepines like diazepam and alprazolam.
• Antidepressants: Avoidance of erythromycin with venlafaxine due to the risk ventricular arrhythmias.
• Antipsychotics: Avoid concomitant use of erythromycin and quetiapine, amisulpride, clozapine, lurasidone and sulpiride.
• Digoxin: There is potential for elevated digoxin levels when used concurrently with erythromycin, which can lead to digoxin toxicity.

Disease Interactions

Erythromycin also interaction with certain diseases:

• Liver Disease: Patients with hepatic impairment are at increased risk for toxicity due to impaired metabolism of erythromycin.
• Cardiac Conditions: Patients with pre-existing arrhythmias or those on other QT-prolonging medications should be monitored closely when prescribed erythromycin.

Management Strategies

To manage potential drug interactions effectively:

• Review Medication History: Always assess a patient's complete medication list before initiating erythromycin therapy.
• Monitor Therapeutic Levels: For drugs with narrow therapeutic indices (e.g. warfarin, digoxin), regular monitoring of blood levels may be necessary.
• Educate Patients: Inform patients about signs of potential drug interactions and advise them to report any unusual symptoms promptly.

FAQ

How Should I Take the Tablet?

Take erythromycin on an empty stomach, ideally one hour before or two hours after meals. Swallow whole; do not crush or chew.

What Should I Avoid while Taking?

Avoid alcohol and grapefruit juice, as they can affect drug metabolism and increase side effects.

What Happens if I Miss a Dose?

If you miss a dose, take it as soon as you remember unless it is almost time for your next does. Do not double up on doses.